NuScale Power [SMR]
⚠️ SUPERSEDED IN PART — 2026-07-29
The position verdict in this document is retired. Under the current framework (
references/criteria.md, 2026-07-29) the memo outputs an analysis, not a position. Whether an analysis justifies a position is a question about a particular book, and two books answer it differently.The Gate block and the Gate 4 expected-return arithmetic below are also superseded, by the named Criteria (each with a type: BINDING or MEASURED, returning PASS / FAIL / INDETERMINATE), the reverse-DCF implied-path test, and a separate 12-month target.
→ Current analysis:
NuScale_Criteria_and_Valuation_2026-07-29.mdEverything else here — the research, the evidence, the mechanism work — stands. Residual references to "Watchlist" in the prose below are the historical record of the 2026-07-27 assessment and are left intact deliberately.
Task 5 · 2026-07-27 · Spot $8.29
POSITION VERDICT: RETIRED 2026-07-29 — the memo outputs an analysis, not a position.
See NuScale_Criteria_and_Valuation_2026-07-29.md for the current Criteria block.
The gate lines below are the 2026-07-27 record and are superseded.
GATES: 1(Mechanism): PASS (strengthened) 2A(Estimate variant): PASS (qualified) 2B(Duration): n/a — short
3(Catalyst): PASS 4(Expected Return): FAIL 5(Feasibility): FAIL 6(Momentum/Tape): PASS
ENTRY: no entry authorised at $8.29 | TARGET (research view): $6.00 (was $6.75) | INVALIDATION: $12.50
TIME HORIZON: n/a — no position. Re-underwrite after the TVA PPA question resolves (guided year-end 2026).
SCENARIO-WEIGHTED E[R] (outright short, 12m): GROSS +2.3% → NET −0.2% after borrow and slippage
(v1.3.0: gross −1.5% / net −4.0%. The thesis got materially better AND the right tail got fatter;
the two corrections nearly cancel, and the gate still fails by 4.9pp against the 4.7% cash hurdle.)
Simple framing: risking ~117% to make ~28%.
SIZING: Conviction Medium-Low (composite 4.5/10) | Volatility HIGH (99.5% realised, beta 3.91)
→ sizing grid output 1% → below minimum viable size for the convexity → rounds down to Watchlist
VEHICLE: none. Both the equity short and every defined-risk options structure priced today have negative E[R].
INVALIDATION / CONVERSION TRIGGERS: see §8
The failure mode this section exists to prevent is reasoning as one narrative ("the company is bad AND expensive AND therefore a short"). The four conclusions are stated independently.
Deteriorating, and the deterioration is observed rather than forecast. Revenue fell 95.8% YoY to $0.565m in Q1-2026; deferred revenue is $1.409m; there are zero binding orders. The company expensed $507.4m and paid ~$495m in cash to ENTRA1 — triggered by a non-binding term sheet. Piotroski F-score 0/9, accruals +0.106, gross profitability 0.008. But: $1,013.9m of cash and investments, zero borrowings, and 5.9 years of runway. This is a business with no revenue and no solvency problem.
ΔE is large on revenue and on the price target; it is zero-to-negative on EPS.
| Street | House | Δ | |
|---|---|---|---|
| FY2026E revenue | $53.5m | $6.6m | −87.7% |
| FY2027E revenue | $169.3m | $18.0m | −89.4% |
| FY2026E EPS | −$0.513 | −$0.51 | in line |
| FY2027E EPS | −$0.734 | −$0.53 | house is better |
| 12m price target | $14.57 (avg) | $6.75 | −54% |
| Implied eventual GW delivery | 18.5 GW | 6.4 GW | −65% |
The variant is real but it is specific: it concerns the revenue trajectory, the ENTRA1 cash-obligation structure, and the implied module count — not the P&L loss, where the Street is already more bearish. Critically, the house target of $6.75 sits between Goldman's $6.00 and Citi's $7.50 — at the bearish edge of the Street, not beyond it.
Under the differentiated forecast, fair value is $6.75 (−18.6%), with a bear at $4.50 and a net-cash floor of $2.76. Today's $2,021.6m EV implies 8.8 GW = 1.47× the entire announced TVA programme must eventually be delivered, against 0.0 GW of binding orders. The stock is demanding relative to contracted reality.
But the probability-weighted target is $8.41 against a spot of $8.29. An 84% drawdown has already discounted most of what this analysis identifies. What is left to capture is roughly 19% of modal downside against a 105% right tail — and that ratio, not the fundamental view, is what decides this memo.
No position. The research conclusion (bearish) and the portfolio action (pass) are different things, and here they diverge. Detail in §3-§7.
A specific, named, evidenced mechanism, not a valuation observation:
NuScale has contracted away the commercialisation of its own product to 2045. ENTRA1 — not NuScale — is the counterparty to every customer document. Under the filed Partnership Milestones Agreement NuScale pays ENTRA1 in cash as commercial progress occurs: ≈$46.98m per 77 MWe module in total (15% on a non-binding letter, 35% on ENTRA1's binding PPA, 50% on the OEM agreement), escalating at the greater of 5% or CPI every 1 January to ≈$63m by a 2031 delivery, guaranteed by the listed parent as primary obligor and payable within 60 days of invoice with no set-off. $507.4m was expensed and fully paid on a non-binding MOU alone. Simultaneously the revenue that funded the P&L (RoPower Doicesti FEED Phase 2) has run off, leaving $0.565m of quarterly revenue and $1.4m of deferred revenue — and management's own guidance for what a TVA PPA is worth in revenue is "about $8 million" on the RoPower analogue, against $207m of Milestone 2 cash per twelve-module plant. A ratio of roughly 26 : 1, cash out to revenue in, at the moment the good news arrives.
Evidence that it is underway, not hypothetical — all from filings:
| Fact | Value | Source |
|---|---|---|
| Q1-26 revenue, YoY | $0.565m, −95.8% | EDGAR XBRL |
| ENTRA1 Milestone 1 expensed | $507.393m | EDGAR us-gaap:BusinessDevelopment FY2025 |
| Cash out on the accrual | $264.2m fall in AP/accrued in Q1-26 | EDGAR XBRL |
| Deferred revenue | $1.409m | EDGAR XBRL |
| Fluor's exit | 39.9m shares Apr-2026, holding → 0 | SEC Form 4 |
| Insider open-market buys, 12m | 0 | SEC Form 4 |
| Total ENTRA1 contribution per NPM | $46.98m (2025) → $62.96m (2031 at the 5% floor) | Derived: $507.393m ÷ 72 ÷ 15%; cross-checked to the 10-K's "approximately $16 million per NPM" ÷ 35% |
| Payment form | Cash, USD wire, 60 days, no set-off, parent-guaranteed | PMA §1(e); Guaranty §2 — filed exhibits, not press |
| Milestone 1 slots reset on advancement, re-arming ≈$533m | 10-K risk factors; PMA §1(a)(i) | The $507m charge is structurally repeatable |
| NRC-docketed sites for the 6-plant programme | 0 | NRC; TVA's only SMR construction permit at Clinch River is a competitor's BWRX-300 |
| Prepared-remarks mentions of "order"/"orders", last 3 calls | 0 and 0 | 16-quarter transcript corpus (data/mention_freq_SMR.json) |
Quantitative corroboration (the standard references/trade-construction.md requires): accruals +0.106
(Sloan 1996 — poor earnings quality), F-score 0/9 (Piotroski 2000 — worst possible), gross profitability
0.008 (Novy-Marx 2013), asset growth +159% (Cooper/Gulen/Schill 2008). This is exactly the empirical
profile in which shorts work; the scorecard does not dissent anywhere on fundamentals. Gate 1 passes on its
strongest possible footing.
Consensus is not already fully bearish, which is the specific risk this gate exists to catch on a −80% momentum name: - 6 of 18 analysts are still Buy or Strong Buy; - the average target is $14.57 = +75.8%; - consensus FY2026 revenue is $53.5m against a $2.3m annualised run-rate — the Street requires a 31× step-up across Q2-Q4 with no announced contract to produce it; - the Q1-2026 print missed consensus revenue by 89.9% and the estimates for Q2 ($11.9m) and Q3 ($16.6m) were only partially cut.
Why consensus is wrong, specifically: the Street is modelling revenue as if NuScale sells reactors. Under the ENTRA1 structure NuScale's near-term revenue is bespoke engineering services to one Romanian project, and that work has run off. The Street is also valuing a successful TVA programme as pure upside while the same event triggers a cash obligation to ENTRA1 that management has never quantified on a call.
v1.4.0 correction, made against the memo's own interest. The prior version put that obligation at $1,246.8m = 123% of the balance sheet, at signature. The filed agreement says otherwise, and the correction must be stated plainly:
| v1.3.0 claim | What the filed PMA says | |
|---|---|---|
| Gross Milestone 2 on 72 NPMs | $1,246.8m | $1,243m at 2026 pricing — essentially right |
| Payable at signature | implied yes | No. Milestone 2 applies to a maximum of 48 NPMs at any one time = $829m; and §1(a)(ii)(b)-(e) bars invoicing more than a redacted number of NPMs before a redacted month in 2027, with the excess payable within 12 months of invoice |
| Payable in cash? | unverified — flagged as the key open question | Yes, unambiguously (§1(e)) — and parent-guaranteed |
| One-time? | treated as such | No. Milestone 1 slots reset on advancement, re-arming ≈$533m of fresh Milestone 1 capacity |
Net effect on the short case: the mechanism is stronger and more permanent, but the near-term funding shock is smaller and later than the prior memo assumed. That is bad for a short, because the funding shock was the only thing that would have offset a PPA announcement's squeeze. It is carried straight into Gate 4 rather than being buried here.
The qualification, stated plainly, not buried: on EPS the Street's FY2027 number (−$0.734) is worse than the house number (−$0.53). And the house price target of $6.75 is not below the Street low of $6.00. This memo is at the bearish edge of published opinion, not beyond it. That materially weakens the "variant" claim relative to a case where the house is alone. Gate 2 passes on revenue and structure; it would fail if the claim were about the loss line.
| Catalyst | Date | Resolves |
|---|---|---|
| Q2-2026 results | 2026-08-05 (9 days) | Directly tests the revenue variant: consensus $11.9m vs. house ~$1.5m. Also discloses Q2 cash, any further ENTRA1 accrual, and any change in the milestone schedule. |
| TVA definitive PPA | Guided "by year-end 2026" | The cleanest possible test. Signature would be filed on an 8-K that must disclose the milestone consequence — resolving in one document both whether the programme is real and what it costs NuScale. |
| Q3-2026 results | ~2026-11-05 | Second revenue datapoint; FY2026 guidance reset. |
| Motion-to-dismiss ruling, Truedson | 1H-2027 (est.) | Whether the disclosure allegations survive. |
These are not "scheduled events near the position" — the Q2 print tests the exact metric Gate 1's mechanism moves, and the PPA tests the exact structural claim. Gate 3 passes cleanly.
Note the asymmetry, because it matters for Gate 4: the TVA catalyst is bidirectional and violent. It is the single strongest catalyst for the short and the single largest squeeze risk.
Scenarios over 12 months to July 2027 (probabilities logged for later calibration scoring). Both the targets and the right tail move under v1.4.0, in opposite directions:
| Scenario | p | Target | Stock return | Return to a SHORT | Contribution |
|---|---|---|---|---|---|
| Bear — no binding PPA; Q2/Q3 confirm ~zero revenue; class action survives MTD; dilutive raise; de-rate toward net cash + option value. Target cut $4.50 → $3.75 on the corrected ENTRA1 fee: at $60m of gross profit per module the fee consumes 78% of it in 2025 dollars and >100% by 2031. | 0.40 | $3.75 | −54.8% | +54.8% | +21.9% |
| Base — muddle-through; talks continue; FY27 revenue $15-30m; ATM resumes; drift. Target cut $6.75 → $6.00 for the same reason. | 0.35 | $6.00 | −27.6% | +27.6% | +9.7% |
| Bull / squeeze — binding TVA PPA (or DOE loan guarantee / first firm order); 20.8%-of-float short base covers. Target raised $17.00 → $18.00: the filed PMA shows the offsetting cash call is capped at 48 slots and largely deferred to 2027, so a PPA announcement now lands with materially less bad news attached than v1.3.0 assumed. | 0.25 | $18.00 | +117.1% | −117.1% | −29.3% |
| GROSS E[R] | +2.3% | ||||
| less stock borrow (12m, est. 0-2%; use 2%) | −2.0% | ||||
| less slippage / financing friction | −0.5% | ||||
| NET E[R] | −0.2% |
Gate 4 still fails, by 4.9 percentage points against the 4.7% cash hurdle — but the margin has narrowed from 8.7pp to 4.9pp, and it is worth being precise about why, because the two effects are independent:
The probability-weighted target is now $8.10 against a spot of $8.29 — a 2.3% gap, versus a negative gap in v1.3.0. There is, for the first time, a sliver of edge. It is nowhere near enough.
What it would take. At p_bull = 0.20 (residual to Bear) the same targets give gross +10.9%, net
+8.4%, clearing the hurdle by 3.7pp. That is the honest statement of how close this is: the entire
decision now rests on one number — the probability of a binding TVA PPA inside twelve months — and management
guides to "later this year." Gate 4's own language still governs ("a mildly positive E[R] with severe
right-tail risk can still fail this gate"), and the right tail here is a documented +109% in 20 sessions.
Per references/alpaca-options.md, the default is a defined-risk spread, not naked premium. Every candidate
was priced from live Alpaca snapshots on 2026-07-27 and every one has negative E[R].
(a) Structural: 15-Jan-2027 $8 / $5 put spread (172 days; spans Q2, Q3 and the guided PPA window)
- Buy SMR270115P00008000 at $2.00 ask (IV 101.3%, δ −0.334) · Sell SMR270115P00005000 at $0.49 bid (IV 103.3%, δ −0.136)
- Net debit $1.51 · width $3.00 · max gain $1.49 · max loss $1.51 · breakeven $6.49 (−21.7%)
- E[R] against 6-month interpolated scenario prices ($5.00 / $7.25 / $15.00 at 40/35/25):
0.40 × (+98.7%) + 0.35 × (−50.3%) + 0.25 × (−100%) = −3.1%
(b) Tactical: 21-Aug-2026 $8 / $6 put spread (25 days; 16 days past the 5-Aug print)
- Buy SMR260821P00008000 at $0.73 ask (IV 104.3%, δ −0.386, OI 6,553) · Sell SMR260821P00006000 at $0.10 bid (IV 112.1%, δ −0.102, OI 4,047)
- Net debit $0.63 · width $2.00 · max gain $1.37 · max loss $0.63 · breakeven $7.37 (−11.1%)
- Requires an 11.1% fall in 25 days merely to break even. The option-implied move is ±22.7%; the house
expected move on a Q2 revenue miss is −10%. The market already prices more downside than the house
forecasts — the explicit Gate 5 options test, failed.
- E[R] across a four-point event distribution ($5.50 / $7.00 / $8.30 / $10.00 at 10/35/35/20): −12.7%
(c) Bear call spread (sell the expensive IV instead of buying it): 21-Aug $10 call at $0.34 bid / $13 call at $0.12 ask ⇒ credit $0.11-0.22 against a max loss of $2.78-2.89. A ~13:1 loss-to-gain ratio on a name that has printed ten +20% single days. Rejected on inspection.
Root cause, stated once: at ~100-112% implied volatility across the surface, the options market has already priced the two-sided distribution correctly. There is no mispriced expression of this view available today.
| Dimension | Finding | Verdict |
|---|---|---|
| Borrow availability | Float 339.3m; ADV 27.0m shares (~$224m/day); Vanguard/BlackRock/Van Eck are natural lenders | Fine |
| Borrow cost | Put-call parity on Jan-27 $8: implied q ≈ 0.5% p.a.; call it 0-2% | Fine — not the constraint |
| Liquidity | ~$224m/day; a 2% book position is a rounding error to the tape | Fine |
| Options liquidity | Aug-21 OI of 4,000-10,000 per strike; spreads $0.01-0.14 | Adequate |
| Short interest / crowding | 70.5m shares = 20.77% of float, up 23.9% between the 31-Mar and 15-Apr settlements | Crowded |
| Days to cover | 2.28 | Bad for a short — the crowd exits in two sessions, and the price of that exit is paid by whoever is still short |
| Retail ownership | 43.4% of the register | Squeeze-prone |
| Realised volatility | 99.5% (1y), 93.2% (3m); beta to SPY 3.91 (1y daily) | Extreme |
| Documented right tail | +109.4% in 20 sessions (2025-04-28 → 2025-05-27); ten separate +20% days since 2022 | Disqualifying |
| Event risk | A binary, bidirectional, unscheduled catalyst (TVA PPA) inside the horizon | Disqualifying |
| Options test | Implied move ±22.7% > house expected move −10% | Fails the stated test |
| Maximum plausible loss | Against the book's −2%-of-book position hard stop: a 2% position is stopped out on a +100% move — a move this name made in 20 sessions 14 months ago | Breaches the book's own risk protocol |
Gate 5 fails, and v1.4.0 does not rescue it — nor could it. As the brief anticipated: a 20.8%-of-float short at 99.5% realised volatility is implementation-constrained regardless of how good the thesis becomes. Better information changes the numerator of the trade; it does not change the borrow crowd, the retail register, the option-implied move, or the book's −2%-of-book hard stop. Nothing in the filed PMA touches any of those.
The failure is not borrow — borrow is cheap and plentiful, which was worth establishing rather than assuming. It is that the maximum plausible loss on any size large enough to matter breaches the book's pre-committed position hard stop, on a catalyst that is scheduled to occur inside the horizon.
12-1 momentum −76.7%; price at 15.5% of the 52-week high; −51.5% vs. the 200-day MA. A short would be with the prevailing momentum, not against it. Gate passes.
The caveat that must be named (Daniel & Moskowitz 2016): momentum crashes hardest precisely in sharp reversals off panicked bottoms in high-volatility, high-short-interest names. SMR — 99.5% realised vol, 20.8% of float short, 43% retail, sitting on a binary catalyst — is close to the canonical momentum-crash setup. So the gate that passes most easily is also the one most likely to reverse violently, which is a reason to weight it less, not more.
portfolio-book contractRead from /Users/oahmady/Desktop/Projects/Investing Hub/portfolio_book.json (as_of 2026-07-27).
| Config | Value |
|---|---|
| Max single-name weight | 5% |
| Max gross / net exposure | 100% / 100% |
| Max pairwise correlation without disclosure | 0.60 |
| Max sector concentration | 25% |
| Cash hurdle (annual) | 4.7% |
| Drawdown ladder | review −5% · degross −10% · stop −15% |
| Position hard stop (book loss) | −2% |
Current state: zero positions; 100% cash; one watchlist entry (NET, short-if-converted).
Dynamic risk protocol note. Had the gates passed, this position would have lived under the −2%-of-book hard stop. At 99.5% realised volatility, the arithmetic is: a 2% short position reaches a −2%-of-book loss on a +100% underlying move; a 1% position on +200%. The name printed +109% in 20 sessions in 2025. The protocol is therefore not a theoretical backstop here — it would very plausibly be triggered, forcing a mechanical cut to half size and a full re-underwrite at the worst possible moment. Sizing a position that the book's own wartime rules would predictably stop out is not risk management, it is a scheduled loss.
Weighted conviction composite per references/trade-construction.md:
| Component | Weight | Score /10 | Contribution | Reasoning |
|---|---|---|---|---|
| Fundamental trajectory (Gate 1) | 25% | 8 | 2.00 | Strong, evidenced, quantitatively corroborated |
| Variant vs. consensus (Gate 2) | 25% | 5 | 1.25 | Real on revenue and structure; absent on EPS; target at the Street low, not beyond |
| Catalyst & timing (Gate 3) | 20% | 6 | 1.20 | Dated and specific — but bidirectional |
| Valuation / payoff (Gate 4) | 15% | 1 | 0.15 | Negative net E[R]; prob-weighted target ≈ spot |
| Balance sheet & risk | 10% | 1 | 0.10 | $1.01bn net cash, zero debt — a headwind for a short |
| Technical / implementation (Gate 5) | 5% | 2 | 0.10 | Borrow fine; crowding, vol and convexity are not |
| 4.5 / 10 | Conviction: Medium-Low |
Volatility tier: HIGH — 99.5% realised (threshold >45%); beta 3.91 (threshold >1.5). Not a guess; computed from Alpaca daily bars.
Sizing grid (house max single-name 5%):
| Conviction \ Volatility | Low | Moderate | High |
|---|---|---|---|
| High | 5% | 3.5% | 2% |
| Medium | 3% | 2% | 1% |
| Low | 1.5% | 1% | below minimum → Watchlist |
Medium-Low conviction × High volatility ⇒ 1% or below ⇒ rounds down to Watchlist, which is where the hard-gate rule had already put it. The two routes agree.
Consensus positioning, stated rather than absorbed into the grid. This would be a position against a Street whose average target implies +75.8% upside — but that consensus is weakening fast (Goldman $9→$6 on 2026-07-15; Barclays $15→$11 on 2026-07-22), and the house target is not below the Street low. So this is not a lonely contrarian call with unquantified crowding risk; it is a call that agrees with the two most bearish houses on the Street. That is a reason not to shrink size for contrarian risk — and it is also a reason to doubt that much excess return remains, since the bear case is already published.
| Vehicle | Assessment |
|---|---|
| Outright equity short | Executable (borrow ~0-2%, $224m/day liquidity) but net E[R] −4.0% with an unbounded convex tail and a scheduled binary catalyst. Rejected. |
| Jan-27 $8/$5 put spread | Defined risk (max loss $1.51/share), but E[R] −3.1%; needs −21.7% by January just to break even at ~101% IV. Rejected. |
| Aug-21 $8/$6 put spread | Defined risk (max loss $0.63), 2.17:1 ratio, but breakeven −11.1% against an implied move of ±22.7%. E[R] −12.7%. Rejected. |
| Aug-21 $10/$13 bear call spread | Sells the rich IV, but ~13:1 loss-to-gain on a name with ten +20% days. Rejected. |
| Naked long puts | Requires the house expected move to materially exceed the implied move. It does the opposite (−10% vs ±22.7%). Prohibited by the rule, and correctly so. |
| Cash | +4.7% risk-free. Wins. |
If the gates were passed at a later date, the vehicle of choice would be the Jan-2027 $8/$5 put spread (or its then-equivalent) — defined risk is mandatory on a name with this right tail, and an outright short would be inappropriate at any size regardless of conviction.
IV-crush disclosure (required whenever a catalyst-dated options trade is discussed, even a rejected one): implied volatility of 104-112% into the 5-Aug print will collapse immediately afterwards regardless of direction. A correct directional call that produces a move smaller than ±22.7% loses money on the August structures. This is a further reason the tactical trade is rejected, not a footnote to it.
The stock is down 83.8% over twelve months and 84.5% from its high. It is fair to ask what remains.
| Already discounted | The CFPP-style execution risk, the revenue collapse, the Iceberg allegations, the Fluor exit, the class action, ~$1.0bn of the FY2025 milestone charge, and most of the sell-side target cuts |
| Not yet discounted (the residual edge) | Roughly 28% of modal downside to $6.00 — the gap between today's implied 29.8 GW and the ~23 GW a Base case supports, on the ENTRA1 fee as filed rather than as reported |
| Newly identified as not discounted | That the ENTRA1 fee is ≈$46.98m per module, not $16m; that it is cash and parent-guaranteed; that it escalates at ≥5% p.a. to 2045; and that Milestone 1 is repeatable. None of this is in any published sell-side note reviewed for the consensus bridge. |
| Cost of trying to capture it | A 117% right tail with a scheduled bidirectional catalyst inside the window |
Ratio: risking ~117% to make ~28%. That is the memo in one line, and it is a better ratio than v1.3.0's 105:19 — but the direction of the improvement matters less than the fact that it is still the wrong side of 1:1 on a name whose catalyst is bidirectional and whose float is a fifth short.
Written to portfolio_book.watchlist (via PENDING_book_and_ledger_updates.json).
No entry is appended to trade_recommendations.jsonl. Per references/recommendation-ledger.md, the ledger
records specific recommendations made; this memo makes none. Every structure priced today was rejected on
negative expected return.
The scenario probabilities (bear 0.40 / base 0.35 / bull 0.25, unchanged) and the revised computed E[R] (gross +2.3%, net −0.2%; v1.3.0 was gross −1.5% / net −4.0%) are recorded here, in the manifest, and in the watchlist entry so that the decision not to trade can be scored later against what actually happened — which is the calibration-relevant artefact even though no capital was committed.
Task 5 executed under investment-memo v1.4.0 (re-run 2026-07-27; supersedes the v1.3.0 pass) and the portfolio-book contract. Options quotes: Alpaca
v1beta1/options/snapshots, 2026-07-27. Price/vol/beta: Alpaca SIP daily bars. Consensus: Alpha Vantage
EARNINGS_ESTIMATES (cached) and stockanalysis.com, 2026-07-27. ENTRA1 terms: SEC EDGAR filed exhibits
0001822966-25-000144 Ex. 10.1/10.2 and 0001822966-25-000088 Ex. 10.1. Transcript corpus: 16 quarters,
Q2-2022–Q1-2026, stockanalysis.com.